What Is THCP-O: Effects, Legality and the Honest Breakdown

THCP-O starts life as THCP, a genuine phytocannabinoid that Citti and colleagues identified in 2019 and published in Scientific Reports. Real plant compound, in other words. THCP occurs naturally in cannabis, though in amounts so small that nobody is extracting it from plant material commercially, and its distinguishing feature is a seven-carbon alkyl side chain where ordinary THC carries five. That longer tail is what makes it interesting to chemists.

Then somebody acetylated it. Reacting THCP with acetic anhydride attaches an acetyl group at the phenolic position, producing THCP-O-acetate with the formula C25H36O3 and a molar mass of roughly 385 g/mol. That reaction is not exotic. It belongs to the same family of chemistry that turns salicylic acid into aspirin, and to the one that produces THC-O from ordinary THC.

That acetyl group does more work than its size suggests, and nearly every question people ask about THCP-O traces back to it. The modification raises the molecule's lipophilicity, so the compound dissolves more readily in fat. The acetylated molecule then behaves as a prodrug: your liver has to strip the acetate group off through deacetylation before anything becomes pharmacologically active at all. Nothing dramatic on paper. That extra metabolic step is why users consistently report a slower onset than with unmodified cannabinoids, and it is also the reason heating it deserves more caution than it usually gets.

None of this is secret. The structure is published and the synthesis route is documented, all of it ordinary organic chemistry. What is missing sits downstream, because no independent laboratory has published pharmacological data on THCP-O in humans. Wikipedia's own entry calls it "allegedly a potent and long-lasting psychoactive cannabinoid". That word is doing considerable work.

Two things in that table deserve a second look. The only genuinely measured number anywhere in this story belongs to THCP, and it measures binding affinity in a dish. That is a long way from how strong something feels in a person. Then look at the independent research row. Not thin. Empty.

The second problem is simpler. That figure describes THCP. THCP-O is a different molecule: structurally modified, metabolised on a different path, never independently measured. Borrowing the number across is a substitution nobody performing it ever bothers to flag.

Set the claims beside the evidence.

• Claimed: THCP-O is around 30 times stronger than THC. Confirmed: THCP shows roughly 33x CB1 binding affinity in vitro. No potency data exists for the acetate in humans.
• Claimed: effects last six to eight hours. Confirmed: consistent across user reports, absent from any controlled study.
• Claimed: it produces a distinctive, long-lasting high. Confirmed: nothing beyond vendor description and self-reported experience.
• Claimed: the compound is well understood. Confirmed: its structure is. Its pharmacology is not.

The timeline gets muddled in the retelling too. THCP was identified in 2019. THCP-O was first synthesised around 2021. Two events, two years, two different molecules, yet you'll find shop pages giving 2019 as the acetate's own origin date, including one retailer whose two articles on the compound give different years (both still live). The confusion is understandable enough. Most of this content was assembled from other blog posts.

The potency figures scatter further. Most German pages settle on roughly thirty times THC, while at least one puts it at three, and a French-language retailer stretches to sixty. Nobody explains the spread. Explaining it would mean admitting where the number came from.

To be fair to the chemistry, a real potency difference is plausible. Acetylation genuinely improves absorption, and THCP's long side chain genuinely binds harder. But plausible is not measured.

What users report is consistent enough to summarise, as long as you hold it loosely. Onset runs slow. Noticeably slower than smoked THC, and that follows straight from the deacetylation step your liver has to run before anything reaches your receptors. Duration reports cluster around six to eight hours. The character of the effect gets described as THC-like but heavier and longer, and everyone offering that description bought the product first. No clinical setting sits behind any of it.

The delayed onset carries a specific practical risk that has nothing to do with the compound's strength. When nothing happens for an hour, taking more feels entirely reasonable. That is the single most common way people end up considerably further out than they planned, and it applies to every acetylated cannabinoid on the market.

• Standard cannabinoid side effects apply: dry mouth, red eyes, elevated heart rate, anxiety or paranoia at higher doses.
• Delayed onset drives redosing. Waiting out an hour of apparently nothing is harder than it sounds.
• Purity varies between sellers, because the compound sits outside any quality-control regime that would standardise it.
• The heating consideration below applies specifically to vaping and dabbing. Other methods do not cross that threshold.

We are describing what people report. Nothing more. On a compound with no published human data, anything firmer would be invention.

Almost nobody writing about THCP-O in German covers this, which is remarkable given that it concerns the most common way people consume the compound. One exception deserves credit: Hanf Magazin runs a dedicated section on it and gets the figures right. Every shop we checked skips it.

Heat a cannabinoid acetate past roughly 340°C and the acetate group can break down, releasing ketene gas. Ketene is toxic at five parts per million. That leaves a narrow margin. Research published in 2022 identified this mechanism as a plausible contributor to vaping-related lung injury, following patterns resembling the EVALI outbreak.

The risk attaches to the acetate group. Which parent cannabinoid it came from barely matters. THCP-O is an acetate ester, and so is THC-O, which we covered in detail in our THC-O article. The same chemistry that makes both absorb so efficiently is what makes overheating them a question worth asking. No seller we found raises it.

Not every device gets there. Whether the threshold is crossed depends on coil temperature and how the liquid is formulated, and plenty of devices never come close to 340°C in normal use. What it does mean is that anybody telling you vaping it carries no unusual risk is making a claim the evidence will not support. The acetate group is the feature and the liability at once. Only the first half turns up in product copy.

Most articles handle this imprecisely, and they miss in one of two directions. Some state that THCP-O was banned on 27 June 2024 alongside HHC and THCP, which arrives at the right outcome by the wrong route. Others claim the reverse, that the compound appeared on the market specifically as a workaround after that ban and therefore sits outside it. The second version is simply wrong. The first is close enough to be useful, but it misses how the ban actually reaches THCP-O, and that mechanism is the interesting part.

Germany's Neue-psychoaktive-Stoffe-Gesetz, the NpSG, does not work by listing individual compounds the way the older narcotics law does. It defines structural groups instead. Anything falling inside a group definition is covered, whether or not anyone has ever written its name into the law. The Fifth Ordinance amending the NpSG annex introduced a new subgroup covering compounds derived from 6H-benzo(c)chromen-1-ol, capturing semi-synthetic designer cannabinoids derived from THC.

The reasoning published alongside that subgroup repays a slow read. It names HHC and several derivatives as examples, using the phrase "among others", which leaves the list open. It then states that the description of substituents covers the acetates that have already appeared, together with their extended variants and their cyclically saturated and aromatic variants. Compounds qualify if they carry the defined core structure and stay under a maximum molecular mass of 600 u.

THCP-O is an acetate. Its seven-carbon side chain makes it precisely an extended variant. Its molar mass of roughly 385 u sits comfortably under the ceiling, and its core structure is the benzo(c)chromen-1-ol skeleton named in the group definition. It falls inside the group.

The lawmakers wrote that definition broadly on purpose, on the assumption that new variants would keep arriving. They were right. A Sixth Ordinance followed in December 2025, widening the same 6H-benzo(c)chromen-1-ol group again to sweep in further derivatives including 10-OH-HHC. The pattern is the point: each new cannabinoid marketed as the legal successor to the last one tends to be standing inside a definition that was written before it launched.

• The ban is real, and it operates through a structural group definition. THCP-O is never named.
• Manufacture, trade, and import are prohibited. The ordinance states explicitly that the intent is to stop commerce without criminalising consumers.
• Possession and personal consumption are not criminalised under the NpSG, which is a genuine and frequently misreported distinction.
• Documentation lags behind the law. Because it is covered by structure rather than by name, you will not find it on a list, which is exactly how sellers create the impression it is unregulated.

If you're in Germany and a shop tells you THCP-O sits in a legal grey area, that framing is doing them more good than it does you. Legal texts usually move slower than product launches. This one was drafted to keep up. Regulation here shifts often enough that you should check a current source before leaning on any of it, this page included.

One detail turned up while researching this article. At least one European retailer that published a THCP-O explainer now shows its product line marked as no longer for sale, while the article itself still ranks and still reads as current. Why, we can't say from the outside. Regulatory pressure, or an ordinary commercial decision. The content outlives the products it was written to sell.

Nine Realms does not sell THCP-O and never has, and this article isn't an argument for or against anyone's choices. No stake in it either way. That is exactly why we could walk through the chemistry and the legal text without needing any of it to land somewhere convenient.

Something about who writes on this topic deserves naming, carefully. Nearly every German-language page currently ranking for THCP-O is published by a company that also sells cannabinoids, in several cases the compound itself. None of them are necessarily dishonest. The writing still sits closer to the till than most readers assume, and that explains how a borrowed potency figure travels so far without anyone stopping to check whose molecule it described.

The distinction that matters is between what is known and what is merely repeated. The structure is documented. Its synthesis is ordinary. Nobody has measured its potency in humans, its legal position in Germany is settled and misreported at the same time, and its heating profile gets attention almost nowhere. If potency and novelty are the appeal, our own T9HC range was built around that same instinct. It comes with lab results you can actually read, and a legal footing that doesn't depend on how a definition gets interpreted.